APOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model

Neurology

Volumn 65, Issue 12, 2005, Pages 1888-1893

  Martins, C A R ^a   Oulhaj, A ^a   De Jager, C A ^a   Williams, J H ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CAMBRIDGE EXAMINATION FOR MENTAL DISORDERS OF ELDERLY; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PREDICTION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL MODEL; GENE DOSAGE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETICS; NEUROPSYCHOLOGICAL TEST; NONLINEAR SYSTEM; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PSYCHOLOGICAL ASPECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NONLINEAR DYNAMICS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 33645742063     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000188871.74093.12     Document Type: Article

References (57)

1. Lahiri DK, Sambamurti K, Bennett DA. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol Aging 2004;25:651-660.
2. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-184.
3. Smith AD, Johnston C, Sim E, et al. Protective effect of apo epsilon 2 in Alzheimer's disease. Oxford Project to Investigate Memory and Ageing (OPTIMA). Lancet 1994;344:473-474.
4. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology 1996;46:673-677.
5. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 1996;19:53-77.
6. Qiu Z, Kivipelto M, Aguero-Torres H, Winblad B, Fratiglioni L. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen Project: variation by age and sex. J Neurol Neurosurg Psychiatry 2004;75:828-833.
7. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease: a meta-analysis. JAMA 1997;278:1349-1356.
8. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580.
9. Saunders AM, Schmader K, Breitner JC, et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993;342:710-711.
10. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
11. Scott J. Apolipoprotein E and Alzheimer's disease. Lancet 1993;342:696.
12. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch Gen Psychiatry 2004;61:518-524.
13. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
14. Locke PA, Conneally PM, Tanzi RE, Gusella JF, Haines JL. Apolipoprotein E4 allele and Alzheimer disease: examination of allelic association and effect on age at onset in both early- and late-onset cases. Genet Epidemiol 1995;12:83-92.
15. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-699.
16. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
17. Growdon JH. Apolipoprotein E and Alzheimer disease. Arch Neurol 1998;55:1053-1054.
18. Lehtovirta M, Laakso MP, Frisoni GB, Soininen H. How does the apolipoprotein E genotype modulate the brain in aging and in Alzheimer's disease? A review of neuroimaging studies. Neurobiol Aging 2000;21:293-300.
19. Bennett DA, Wilson RS, Schneider JA, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 2003;60:246-252.
20. Raber J, Huang Y, Ashford JW. APOE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004;25:641-650.
21. Wahlund LO, Julin P, Lannfelt L, Lindqvist J, Svensson L. Inheritance of the APOE epsilon4 allele increases the rate of brain atrophy in dementia patients. Dement Geriatr Cogn Disord 1999;10:262-268.
22. Geroldi C, Pihlajamaki M, Laakso MP, et al. APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999;53:1825-1832.
23. Juottonen K, Lehtovirta M, Helisalmi S, Riekkinen PJ, Sr., Soininen H. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J Neurol Neurosurg Psychiatry 1998;65:322-327.
24. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-761.
25. Morishima-Kawashima M, Oshima N, Ogata H, et al. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 2000;157:2093-2099.
26. Ohm TG, Kirca M, Bohl J, Scharnagl H, Gross W, Marz W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995;66:583-587.
27. Geroldi C, Laakso MP, DeCarli C, et al. Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study. J Neurol Neurosurg Psychiatry 2000;68:93-96.
28. Barber R, Gholkar A, Scheltens P, et al. Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol 1999;56:961-965.
29. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996;47:444-448.
30. Dal Forno G, Rasmusson DX, Brandt J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 1996;53:345-350.
31. Jonker C, Schmand B, Lindeboom J, Havekes LM, Launer LJ. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 1998;55:1065-1069.
32. Kurz A, Egensperger R, Haupt M, et al. Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996;47:440-443.
33. Asada T, Kariya T, Yamagata Z, Kinoshita T, Asaka A. APOE epsilon 4 allele and cognitive decline in patients with Alzheimer's disease. Neurology 1996;47:603.
34. Frisoni GB, Govoni S, Geroldi C, et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995;37:596-604.
35. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997;41:615-620.
36. Hyot BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol 2005;62:454-459.
37. Craft S, Teri L, Edland SD, et al. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 1998;51:149-153.
38. Wilson RS, Bennett DA, Bienias JL, et al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology 2002;59:1910-1914.
39. Hirono N, Hashimoto M, Yasuda M, Kazui H, Mori E. Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon4 allele. J Neuropsychiatry Clin Neurosci 2003;15:354-358.
40. Marra C, Bizzarro A, Daniele A, et al. Apolipoprotein E epsilon4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients. Dement Geriatr Cogn Disord 2004;18:125-131.
41. Plassman BL, Breitner JC. Apolipoprotein E and cognitive decline in Alzheimer's disease. Neurology 1996;47:317-320.
42. Roth M, Huppert FA, Mountjoy CQ, Tym E. CAMDEX-R: the Cambridge Examination for Mental Disorder of the Elderly. Rev. ed. Cambridge, UK: Cambridge University Press, 1988.
43. Folstein M, Folstein S, McHugh P. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
44. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
45. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-1159.
46. Liu X, Tsai W, Stern Y. A functional decline model for prevalent cohort data. Stat Med 1996;15:1023-1032.
47. Stern Y, Lui X, Albert M, et al. Modeling the interference of extrapiramidal signs on the progression of Alzheimer's disease. Arch Neurol 1996;53:1121-1126.
48. Rosenthal R, Rosnow RL, Donald BR. Contrasts and effect sizes in behavioral research: a correlational approach. Cambridge, UK: Cambridge University Press, 2000.
49. SAS Institute I. SAS/STAT user's guide version 9.1. Cary, NC: SAS Institute, 2004.
50. de Koning I, van Kooten F, Dippel DW, et al. The CAMCOG: a useful screening instrument for dementia in stroke patients. Stroke 1998;29:2080-2086.
51. Tsolaki M, Fountoulakis KN, Chantzi H, Kazis A. The Cambridge Cognitive Examination (CAMCOG): a validation study in outpatients suffering from dementia and non-demented elderly subjects (including age associated cognitive decline patients) in Greece. Am J Alz Dis 2000;269-276.
52. Williams JG, Huppert FA, Mathews FE, Nickson J, Study MCFaA. Performance and normative values of a concise neuropsychological test (CAMCOG) in an elderly population sample. Int J Geriatr Psychiatry 2003;18:631-644.
53. Bannister C, Ballard C, Lana M, Fairbairn A, Wilcock G. Placement of dementia sufferers in residential and nursing home care. Age Ageing. 1998;27:189-193.
54. Sakamoto Y, Ishiguro M, Kitigawa G. Aikake information criterion statistics. Dordrecht, Holland: Riedel, 1986.
55. Schmand B, Walstra G, Lindeboom J, Teunisse S, Jonker C. Early detection of Alzheimer's disease using the Cambridge Cognitive Examination (CAMCOG). Psychol Med 2000;30:619-627.
56. De Jager CA, Hogervorst E, Combrinck M, Budge MM. Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease. Psychol Med 2003;33:1039-1050.
57. Koivisto AM, Lempiainen P, Koivisto K, et al. Apolipoprotein E phenotype alone does not influence survival in Alzheimer's disease: a population-based longitudinal study. Neuroepidemiology 2000;19:327-332.